Related references
Note: Only part of the references are listed.The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis
Kevin M. Pantalone et al.
ACTA DIABETOLOGICA (2009)
Glibenclamide-related excess in total and cardiovascular mortality risks: Data from large Ukrainian observational cohort study
Mykola Khalangot et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2009)
Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study
Henriette T. Horsdal et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2009)
No differences in mortality between users of pancreatic-specific and non-pancreatic-specific sulphonylureas: a cohort analysis
Josie M. M. Evans et al.
DIABETES OBESITY & METABOLISM (2008)
SUR receptor activity vs. incidence of hypoglycaemia and cardiovascular mortality with sulphonylurea therapy for diabetics
J. Tayek
DIABETES OBESITY & METABOLISM (2008)
A systematic review and meta-analysis of hypoglycemia and cardiovascular event - A comparison of glyburide with other secretagogues and with insulin
Azim S. Gangji et al.
DIABETES CARE (2007)
Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin
JMM Evans et al.
DIABETOLOGIA (2006)
Effects of glimepiride and glyburide on glucose counterregulation and recovery from hypoglycemia
E Szoke et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2006)
Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes
JA Johnson et al.
DIABETIC MEDICINE (2005)
Sulphonylurea action revisited - the post-cloning era
FM Gribble et al.
DIABETOLOGIA (2003)
Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes
JA Johnson et al.
DIABETES CARE (2002)
Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide
MM Mocanu et al.
CIRCULATION (2001)
Glimepiride block of cloned ß-cell, cardiac and smooth muscle KATP channels
DK Song et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
The abuse of power: The pervasive fallacy of power calculations for data analysis
JM Hoenig et al.
AMERICAN STATISTICIAN (2001)
Share Paper
